Treace Medical Concepts, Inc. appears in FDA premarket records as the applicant behind a family of Class II bone-fixation devices regulated under 21 CFR 888.3030 and 888.3040. The company's own published surgical technique and instructions for use describe the TMC Implant Fixation System - Compression Implant System as implants made of titanium alloy conforming to ASTM F136, together with locking screws, compression implants and related instrumentation offered in multiple bridge lengths, leg lengths and cross sections. The company's website describes Treace as a medical technology company focused on surgical treatment of bunions and foot and ankle conditions, and credits it with the Lapiplasty 3D Bunion Correction System. [1][2][3][5][8]
Documented fixation products and materials
The manufacturer's instructions for use state that the TMC Implant Fixation System - Compression Implant System consists of implants composed of titanium alloy conforming to ASTM F136 and related instrumentation for implantation, with locking screws and compression implants in multiple combinations of bridge lengths, leg lengths and cross sections. The surgical technique document covers Lapidus, lesser TMT and first MTP fusion and notes that implant selection and preoperative consideration of the fixation option affect the potential for surgical success. [3][5]
Treace's website lists first-ray, midfoot and hindfoot systems, naming Lapiplasty, HyperPlate XM compression locking implants, and SuperBite fully-threaded compression screws, alongside instruments such as the SureFire MTP Targeting Guide, SpeedMTP and GreatRelease. These are product identities published by the manufacturer, not independently verified performance claims. [6]
Regulatory record and dated submissions
The FDA 510(k) record K262963 covers the TMC Implant Fixation System under regulation number 21 CFR 888.3030, Class II, product codes HRS, JDR and HWC, with a decision date of September 15, 2026 and a decision of substantially equivalent. The clearance letter is addressed to Melissa Coloroso, Principal Regulatory Affairs Specialist, at 100 Palmetto Park Pl., Ponte Vedra, Florida, and states that the subject devices are substantially equivalent to the predicate devices. [1][2]
An earlier clearance, K251135, dated August 21, 2025, covers the same TMC Implant Fixation System trade name under 21 CFR 888.3030 and states that analysis demonstrated the subject devices met all acceptance criteria and are substantially equivalent to the predicate devices. A separate March 6, 2026 letter for K260361 covers the TMC Screw Fixation System under 21 CFR 888.3040, Class II, product code HWC, and states that the described changes do not affect reprocessing, biocompatibility or sterility considerations relative to the predicate devices. [4][9]
Collection scope and what the filings do not establish
The linked collection retrieved for this profile contains one 510(k) record, K262963, and its decision count is one substantially equivalent decision; the single-record sample shows the same one substantially equivalent outcome. These figures describe the retrieved filings as of the snapshot date and are not measures of total company sales, total portfolio breadth or safety performance. [1]
The FDA records identify the applicant and the cleared device names, regulation numbers, classes and product codes, but they do not establish ownership structure, headquarters, customers or commercial availability. The Ponte Vedra, Florida address appears as the correspondence address in FDA letters and as the manufacturer address in the instructions for use; it is not treated here as a verified headquarters. [2][5]
Company identity as published
Treace's about page describes the company as aiming to be the recognized leader in surgical treatment of bunions and foot and ankle conditions, states that bunions affect approximately 67 million Americans with an estimated 1.1 million annual surgical candidates, and credits Treace with pioneering and patenting the Lapiplasty 3D Bunion Correction System, a combination of instruments, implants and surgical methods. Those figures and characterizations are the manufacturer's own published statements. [8]


